ENDOTOXIN TOLERANCE AS A MODEL FOR IMMUNE PARALYSIS

内毒素耐受作为免疫麻痹的模型

基本信息

  • 批准号:
    6127300
  • 负责人:
  • 金额:
    $ 25.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-03-15 至 2004-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (adapted from applicant's abstract) The applicants propose to study the pathogenesis and biologic significance of injury-induced defects in the innate cellular immune response. These include studies of both experimental endotoxin tolerance in mice and clinical immune paralysis in cardiac surgery patients. Endotoxin tolerance is induced by repeated exposures to lipopolysaccharide (endotoxin) and results in reduced synthesis of pro-inflammatory cytokines to microbial stimuli. Immune paralysis is phenotypically similar, but is a clinical phenomenon induced by sepsis or trauma. They hypothesize that endotoxin tolerance and immune paralysis disrupt the interdependent production and synergistic anti-microbial activities of TNF-alpha, IL-12 and IFN-gamma that mediate the innate cellular immune response. Their first goal is to use the well-characterized mouse model of endotoxin tolerance to identify mechanisms that mediate the immune defects of endotoxin tolerance and enhance susceptibility to infection. They will then identify interventions that prevent or reverse these immune deficiencies. Preliminary data already indicate immune cell depletion is a mechanism for injury-induced cytokine deficiency and identify a 10- to 10,000-fold enhanced susceptibility to candidiasis during endotoxin tolerance. The applicants' second goal is to study the biologic basis and epidemiologic consequence of immune paralysis in cardiac surgery patients, with a long term goal of developing clinical interventions to prevent immune paralysis. The specific aims of this proposal are: 1) Identify molecular and/or cellular defects in the innate immune response of endotoxin tolerant mice. 2) Determine if the defective innate immunity of endotoxin tolerance enhances susceptibility to common nosocomial pathogens. 3) Use these findings to rationally design drug or cytokine therapies that prevent the immune defects of endotoxin tolerance and thereby reduce susceptibility to nosocomial superinfection. 4) Characterize comparable cytokine and cellular defects in hospitalized patients following cardiac surgery and identify immune phenotypic markers predictive of post-operative infections. Studies of the immune pathogenesis of infectious susceptibility in endotoxin tolerant mice are likely to suggest cytokine- or anti-apoptosis-based therapies for clinical immune paralysis. This is a clinically desirable goal, as the preservation or enhancement of innate immunity against nosocomial infections in injured patients may significantly reduce hospital morbidity, costs, antibiotic use and the selection of antibiotic-resistant pathogens.
描述(改编自申请人摘要)申请人拟参加学习

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FREDERICK P. HEINZEL其他文献

FREDERICK P. HEINZEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FREDERICK P. HEINZEL', 18)}}的其他基金

ENDOTOXIN TOLERANCE AS A MODEL FOR IMMUNE PARALYSIS
内毒素耐受作为免疫麻痹的模型
  • 批准号:
    6632103
  • 财政年份:
    2000
  • 资助金额:
    $ 25.41万
  • 项目类别:
ENDOTOXIN TOLERANCE AS A MODEL FOR IMMUNE PARALYSIS
内毒素耐受作为免疫麻痹的模型
  • 批准号:
    6511013
  • 财政年份:
    2000
  • 资助金额:
    $ 25.41万
  • 项目类别:
ENDOTOXIN TOLERANCE AS A MODEL FOR IMMUNE PARALYSIS
内毒素耐受作为免疫麻痹的模型
  • 批准号:
    6362421
  • 财政年份:
    2000
  • 资助金额:
    $ 25.41万
  • 项目类别:
INTERLEUKIN-12 AS IMMUNOTHERAPY IN LEISHMANIASIS
INTERLEUKIN-12 作为利什曼病的免疫疗法
  • 批准号:
    2071988
  • 财政年份:
    1994
  • 资助金额:
    $ 25.41万
  • 项目类别:
INTERLEUKIN 12 FUNCTION DURING MURINE LEISHMANIASIS
鼠利什曼病期间白细胞介素 12 的功能
  • 批准号:
    2057400
  • 财政年份:
    1994
  • 资助金额:
    $ 25.41万
  • 项目类别:
INTERLEUKIN 12 FUNCTION DURING MURINE LEISHMANIASIS
鼠利什曼病期间白细胞介素 12 的功能
  • 批准号:
    2057399
  • 财政年份:
    1994
  • 资助金额:
    $ 25.41万
  • 项目类别:
INTERLEUKIN 12 FUNCTION DURING MURINE LEISHMANIASIS
鼠利什曼病期间白细胞介素 12 的功能
  • 批准号:
    2057398
  • 财政年份:
    1994
  • 资助金额:
    $ 25.41万
  • 项目类别:
INTERLEUKIN 12 AS IMMUNOTHERAPY IN LEISHMANIASIS
白细胞介素 12 作为利什曼病的免疫治疗
  • 批准号:
    6169986
  • 财政年份:
    1994
  • 资助金额:
    $ 25.41万
  • 项目类别:
INTERLEUKIN 12 AS IMMUNOTHERAPY IN LEISHMANIASIS
白细胞介素 12 作为利什曼病的免疫治疗
  • 批准号:
    2886914
  • 财政年份:
    1994
  • 资助金额:
    $ 25.41万
  • 项目类别:
INTERLEUKIN-12 AS IMMUNOTHERAPY IN LEISHMANIASIS
INTERLEUKIN-12 作为利什曼病的免疫疗法
  • 批准号:
    2071989
  • 财政年份:
    1994
  • 资助金额:
    $ 25.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了